Paion (PAIO.F) Stock Overview

A specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. More details

PAIO.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

Does not have a meaningful market cap ($398K)

PAIO.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW437,192 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

437,192 investors already sharing narratives

View all narratives

Paion AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Paion
Historical stock prices
Current Share Price	€0.07
52 Week High	€0.07
52 Week Low	€0.01
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	600.00%
3 Year Change	-98.83%
5 Year Change	-99.69%
Change since IPO	-99.90%

Recent updates

Shareholder Returns

	PAIO.F	US Biotechs	US Market
7D	0%	-4.4%	-0.2%
1Y	600.0%	39.9%	14.8%

Return vs Industry: PAIO.F exceeded the US Biotechs industry which returned 39.9% over the past year.

Return vs Market: PAIO.F exceeded the US Market which returned 14.8% over the past year.

Price Volatility

Is PAIO.F's price volatile compared to industry and market?
PAIO.F volatility
PAIO.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stable Share Price: PAIO.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PAIO.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Gregor Siebert	www.paion.com

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

Paion AG Fundamentals Summary

How do Paion's earnings and revenue compare to its market cap?
PAIO.F fundamental statistics
Market cap	US$398.07k
Earnings (TTM)	-US$23.09m
Revenue (TTM)	US$17.21m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is PAIO.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAIO.F income statement (TTM)
Revenue	€14.81m
Cost of Revenue	€6.35m
Gross Profit	€8.46m
Other Expenses	€28.32m
Earnings	-€19.86m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PAIO.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/10 23:09
End of Day Share Price	2026/07/16 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Paion AG is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Savin	Edison Investment Research
Simon Scholes	First Berlin Equity Research GmbH
Martial Descoutures	ODDO BHF Corporate & Markets

Paion AGOTCPK:PAIO.F Stock Report